JPWO2020172328A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020172328A5 JPWO2020172328A5 JP2021548697A JP2021548697A JPWO2020172328A5 JP WO2020172328 A5 JPWO2020172328 A5 JP WO2020172328A5 JP 2021548697 A JP2021548697 A JP 2021548697A JP 2021548697 A JP2021548697 A JP 2021548697A JP WO2020172328 A5 JPWO2020172328 A5 JP WO2020172328A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- modified
- mil
- population
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962808031P | 2019-02-20 | 2019-02-20 | |
| US62/808,031 | 2019-02-20 | ||
| PCT/US2020/018897 WO2020172328A1 (en) | 2019-02-20 | 2020-02-19 | Expansion of natural killer and chimeric antigen receptor-modified cells |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022520871A JP2022520871A (ja) | 2022-04-01 |
| JP2022520871A5 JP2022520871A5 (https=) | 2023-02-10 |
| JPWO2020172328A5 true JPWO2020172328A5 (https=) | 2023-02-10 |
| JP7575104B2 JP7575104B2 (ja) | 2024-10-29 |
Family
ID=72143864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021548697A Active JP7575104B2 (ja) | 2019-02-20 | 2020-02-19 | ナチュラルキラー細胞およびキメラ抗原受容体改変された細胞の拡大増殖 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12453773B2 (https=) |
| EP (1) | EP3927730A4 (https=) |
| JP (1) | JP7575104B2 (https=) |
| CN (1) | CN113710691B (https=) |
| CA (1) | CA3131879A1 (https=) |
| WO (1) | WO2020172328A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| EP3746095A4 (en) | 2018-02-01 | 2021-04-21 | Nkmax Co., Ltd. | Method of producing natural killer cells and composition for treating cancer |
| EP4209586B1 (en) * | 2020-09-04 | 2025-10-29 | Daegu Gyeongbuk Institute Of Science and Technology | Extracellular vesicle expressing cytokine and antibody, method for producing same, and use thereof |
| EP4501336A4 (en) * | 2022-03-24 | 2025-10-15 | Therabest Co Ltd | Pharmaceutical composition for the prevention or treatment of degenerative brain diseases with natural killer cells |
| WO2023205733A1 (en) * | 2022-04-21 | 2023-10-26 | Academia Sinica | Genetically engineered innate lymphoid cells for enhancing lifespan and/or treating cancers |
| CN114736859B (zh) * | 2022-06-13 | 2022-08-19 | 广东先康达生物科技有限公司 | 一种脐带血nk细胞的培养液及培养方法 |
| CN116254230A (zh) * | 2022-09-14 | 2023-06-13 | 卡瑞济(北京)生命科技有限公司 | 用于制备和扩增通用型人源化抗cd19 car-nk细胞的方法及其用途 |
| CN115612673A (zh) * | 2022-12-14 | 2023-01-17 | 卡瑞济(北京)生命科技有限公司 | 一种改善car-t细胞群的持久性的方法 |
| CN116554300B (zh) * | 2023-04-27 | 2023-10-24 | 湖北医药学院 | 一种能与艰难拟梭菌毒素TcdB相互作用的多肽及其应用 |
| AU2024298429A1 (en) * | 2023-07-21 | 2026-01-29 | Gaia Biomedicine Inc. | Method for producing cell population |
| CN117187181B (zh) * | 2023-11-08 | 2024-03-19 | 普华赛尔生物医疗科技有限公司 | 包被组合物的方法及其应用 |
| WO2025178407A1 (ko) * | 2024-02-23 | 2025-08-28 | 마루테라퓨틱스 주식회사 | 고효율 유도 자연살해세포(ink) 증식 방법 |
| WO2025251226A1 (en) * | 2024-06-05 | 2025-12-11 | Nuwacell Biotechnologies Co., Ltd. | Use of interleukin-21 and interleukin-15 for enhancing serial killing of natural killer cell for cell therapy against target cell |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7005127B2 (en) | 2002-03-29 | 2006-02-28 | Tissuegene, Inc. | Mixed-cell gene therapy |
| CN102559600A (zh) * | 2011-12-29 | 2012-07-11 | 上海交通大学医学院 | 一种人工抗原递呈细胞及其在nk细胞扩增中的应用 |
| WO2015154012A1 (en) * | 2014-04-03 | 2015-10-08 | Memorial Sloan-Kettering Cancer Center | Clonogenic natural killer (nk) cell populations and methods of producing and using such populations |
| AU2015273501B2 (en) * | 2014-06-11 | 2021-01-21 | Polybiocept Gmbh | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy |
| CN109844099B (zh) * | 2016-07-25 | 2024-01-02 | 美国政府(由卫生和人类服务部的部长所代表) | 产生经修饰的自然杀伤细胞的方法及使用方法 |
| CA3041831A1 (en) * | 2016-10-27 | 2018-05-03 | Intima Bioscience, Inc. | Viral methods of making genetically modified cells |
| MX2019011570A (es) * | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
-
2020
- 2020-02-19 EP EP20758646.2A patent/EP3927730A4/en active Pending
- 2020-02-19 CN CN202080029826.4A patent/CN113710691B/zh active Active
- 2020-02-19 WO PCT/US2020/018897 patent/WO2020172328A1/en not_active Ceased
- 2020-02-19 CA CA3131879A patent/CA3131879A1/en active Pending
- 2020-02-19 US US17/432,380 patent/US12453773B2/en active Active
- 2020-02-19 JP JP2021548697A patent/JP7575104B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020172328A5 (https=) | ||
| Engels et al. | Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes | |
| Rezvani et al. | Engineering natural killer cells for cancer immunotherapy | |
| Hughes et al. | Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions | |
| Sharpe et al. | Genetically modified T cells in cancer therapy: opportunities and challenges | |
| DK0765386T3 (en) | Methods for T cell activation in vivo with antigen-incubated dendritic cells | |
| JP2022184852A5 (https=) | ||
| JP2021509287A (ja) | キメラ抗原受容体（ｃａｒ）またはトランスジェニックｔ細胞受容体（ｔｃｒ）の発現のためのウイルスベクターで細胞を形質導入するための方法 | |
| Murad et al. | Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressing T cells for autologous adoptive cell therapy | |
| JP2024086827A5 (https=) | ||
| US20210379149A1 (en) | Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy | |
| EP3529351A1 (en) | Targeted gene insertion for improved immune cells therapy | |
| US20240287456A1 (en) | A method for producing antigen-specific t cells | |
| EP2097098A1 (en) | Expression of transgenic t cell receptors in lak-t cells | |
| Zhu et al. | Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy | |
| WO1997022349A1 (en) | Methods for in vivo t cell activation by antigen-pulsed dendritic cells | |
| Santini et al. | Advances in the use of dendritic cells and new adjuvants for the development of therapeutic vaccines | |
| US20240190988A1 (en) | Novel chimeric antigen receptors and libraries | |
| KR20220148809A (ko) | Hbv 특이적 tcr 라이브러리 및 맞춤형 의약으로서의 이의 용도 | |
| AU2019369137A1 (en) | Modified PDC line for secreting a cytokine | |
| Sahin et al. | Natural killer cell-mediated cellular therapy of hematological malignancies | |
| US9205111B2 (en) | Process for producing engineered targeted T cell and medicine | |
| JP7847359B2 (ja) | Ｎｋ細胞の培養方法 | |
| Kühnel et al. | Engineered Natural Killer Cell Lines and Their Application for Cancer Immunotherapy | |
| Engels | Optimisation of retroviral gene transfer in T lymphocytes for the redirection of PBL-specificity |